论文部分内容阅读
目的分析小剂量尿激酶与低分子肝素钙联合治疗进展性脑血栓的临床效果。方法 94例进展性脑血栓患者,按照随机双盲法分为治疗组和对照组,各47例。对照组患者采取常规治疗,治疗组患者在常规治疗时联合小剂量尿激酶与低分子肝素钙治疗。比较两组临床疗效。结果治疗组总有效率(95.7%)高于对照组(72.3%)(P<0.05);治疗后治疗组神经功能缺损程度明显减轻,且优于对照组(P<0.05);两组患者在治疗期间无不良反应出现。结论小剂量尿激酶与低分子肝素钙联合治疗进展性脑血栓效果显著,临床应用价值高。
Objective To analyze the clinical effect of combination of low-dose urokinase and low-molecular-weight heparin in the treatment of progressive cerebral thrombosis. Methods 94 patients with progressive cerebral thrombosis were randomly divided into treatment group and control group according to a randomized double-blind method, with 47 cases in each group. Control group of patients taking conventional treatment, the treatment group patients in the conventional treatment combined with low-dose urokinase and low molecular weight heparin treatment. The clinical efficacy of the two groups were compared. Results The total effective rate (95.7%) in the treatment group was significantly higher than that in the control group (72.3%) (P <0.05). After treatment, the degree of neurological deficit in the treatment group was significantly lower than that in the control group (P <0.05) No adverse reactions occurred during treatment. Conclusions The combination of low-dose urokinase and low-molecular-weight heparin calcium is effective in treating cerebral thrombosis and has high clinical value.